<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1375" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1375/" /><meta name="ncbi_pagename" content="Familial Hyperinsulinism - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Familial Hyperinsulinism - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Familial Hyperinsulinism" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/03/21" /><meta name="citation_author" content="David Gillis" /><meta name="citation_pmid" content="20301549" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1375/" /><meta name="citation_keywords" content="Congenital Hyperinsulinism (CHI)" /><meta name="citation_keywords" content="Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)" /><meta name="citation_keywords" content="Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)" /><meta name="citation_keywords" content="Congenital Hyperinsulinism (CHI)" /><meta name="citation_keywords" content="ATP-binding cassette sub-family C member 8" /><meta name="citation_keywords" content="ATP-sensitive inward rectifier potassium channel 11" /><meta name="citation_keywords" content="Glutamate dehydrogenase 1, mitochondrial" /><meta name="citation_keywords" content="Hepatocyte nuclear factor 4-alpha" /><meta name="citation_keywords" content="Hexokinase-4" /><meta name="citation_keywords" content="Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial" /><meta name="citation_keywords" content="Mitochondrial uncoupling protein 2" /><meta name="citation_keywords" content="ABCC8" /><meta name="citation_keywords" content="GCK" /><meta name="citation_keywords" content="GLUD1" /><meta name="citation_keywords" content="HADH" /><meta name="citation_keywords" content="HNF4A" /><meta name="citation_keywords" content="KCNJ11" /><meta name="citation_keywords" content="UCP2" /><meta name="citation_keywords" content="Familial Hyperinsulinism" /><meta name="citation_keywords" content="Overview" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Familial Hyperinsulinism" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="David Gillis" /><meta name="DC.Date" content="2019/03/21" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1375/" /><meta name="description" content="The purpose of this overview is to increase the awareness of clinicians regarding familial hyperinsulinism (referred to as FHI in this GeneReview) and its genetic causes and management." /><meta name="og:title" content="Familial Hyperinsulinism" /><meta name="og:type" content="book" /><meta name="og:description" content="The purpose of this overview is to increase the awareness of clinicians regarding familial hyperinsulinism (referred to as FHI in this GeneReview) and its genetic causes and management." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1375/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hi/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1375/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D25FCE03FD8F10000000005FC0221.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1375_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1375_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hyperchol/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/lpl/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1375_"><span class="title" itemprop="name">Familial Hyperinsulinism</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Congenital Hyperinsulinism (CHI), Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)</div><p class="contrib-group"><span itemprop="author">David Gillis</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1375_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1375_ai__"><div class="contrib half_rhythm"><span itemprop="author">David Gillis</span>, MD<div class="affiliation small">Hadassah Hebrew University Hospital<br />Jerusalem, Israel<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="li.gro.hassadah@silligd" class="oemail">li.gro.hassadah@silligd</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 19, 2003</span>; Last Update: <span itemprop="dateModified">March 21, 2019</span>.</p><p><em>Estimated reading time: 25 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hi.Summary" itemprop="description"><h2 id="_hi_Summary_">Summary</h2><p>The purpose of this overview is to increase the awareness of clinicians regarding <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hyperinsulinism (referred to as FHI in this <i>GeneReview</i>) and its genetic causes and management.</p><p>The following are the goals of this overview.</p><div><h4 class="inline">Goal 1.</h4><p>Describe the <a href="#hi._escape__1_Clinical_Characteristics_o">clinical characteristics</a> of FHI.</p></div><div><h4 class="inline">Goal 2.</h4><p>Review the <a href="#hi._escape__2_Genetic_Causes_of_Familial">genetic causes</a> of FHI.</p></div><div><h4 class="inline">Goal 3.</h4><p>Provide an <a href="#hi._escape__3_Evaluation_Strategies_to_I">evaluation strategy</a> to identify the genetic cause of FHI in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> (when possible).</p></div><div><h4 class="inline">Goal 4.</h4><p>Inform (when possible) <a href="#hi._escape__4_Medical_Management_of_FHI">medical management</a> of FHI based on genetic cause and evaluation of relatives at risk.</p></div><div><h4 class="inline">Goal 5.</h4><p>Inform <a href="#hi._escape__5_Risk_Assessment_and_Survei">risk assessment and surveillance</a> of at-risk relatives for early detection and treatment of FHI.</p></div></div><div id="hi._escape__1_Clinical_Characteristics_o"><h2 id="_hi__escape__1_Clinical_Characteristics_o_">1. Clinical Characteristics of Familial Hyperinsulinism</h2><div id="hi.Clinical_Manifestations"><h3>Clinical Manifestations</h3><p>Familial hyperinsulinism (FHI) is characterized by hypoglycemia that ranges from severe neonatal onset to childhood onset with mild symptoms. Neonatal-onset disease manifests within hours to days after birth. In the newborn period, presenting symptoms may be nonspecific, including seizures, hypotonia, poor feeding, and apnea. Childhood-onset disease manifests during the first months or years of life and can present with an unprovoked seizure or laboratory evidence of hypoglycemia noted during acute illness during which nutritional intake is reduced. Some individuals may be asymptomatic. Even within the same family, disease manifestations can range from mild to severe and clinical presentation can range from immediately after birth to late in childhood.</p></div><div id="hi.Laboratory_Features"><h3>Laboratory Features</h3><p>In most individuals, FHI can be definitively and rapidly diagnosed if the appropriate laboratory tests are done on blood and urine samples during an episode of spontaneous hypoglycemia or during monitored fasting (glucose &#x0003c;50 mg/dL) (see <a class="figpopup" href="/books/NBK1375/table/hi.T.diagnostic_tests_for_documentation/?report=objectonly" target="object" rid-figpopup="fighiTdiagnostictestsfordocumentation" rid-ob="figobhiTdiagnostictestsfordocumentation">Table 1</a>).</p><div id="hi.T.diagnostic_tests_for_documentation" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Diagnostic Tests for Documentation of Hyperinsulinism</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1375/table/hi.T.diagnostic_tests_for_documentation/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hi.T.diagnostic_tests_for_documentation_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Specimen Type</th><th id="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Laboratory Test</th><th id="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Expected Result in Hyperinsulinism</th></tr></thead><tbody><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_1" rowspan="11" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Blood</b></td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Insulin</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inappropriately elevated</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">C-peptide</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Free fatty acids</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inappropriately low</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">&#x003b2;-hydroxybutyrate</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inappropriately low</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Acetoacetate</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inappropriately low</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Lactic acid</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Carnitine</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Growth hormone</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated due to hypoglycemia</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Cortisol</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated due to hypoglycemia, although not always, particularly if hypoglycemia is of short duration&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">T<sub>4</sub>, T<sub>3</sub>, TSH</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Ammonia</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated in hyperinsulinism/hyperammonemia syndrome only</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Urine</b></td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ketone bodies (at time of hypoglycemia)</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Negative</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Reducing substances</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Negative</td></tr><tr><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">C-peptide</td><td headers="hd_h_hi.T.diagnostic_tests_for_documentation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">TSH = thyroid-stimulating hormone</p></div></dd><dt></dt><dd><div><p class="no_margin">Reprinted from <a class="bk_pop" href="#hi.REF.glaser.1999.55">Glaser et al [1999]</a> with permission from Elsevier</p></div></dd><dt>1. </dt><dd><div id="hi.TF.1.1"><p class="no_margin"><a class="bk_pop" href="#hi.REF.hussain.2003">Hussain et al [2003]</a></p></div></dd></dl></div></div></div><p><b>Glucagon stimulation test.</b> A glycemic response of &#x0003e;30 mg/dL following injection of 0.03 mg/kg glucagon excludes a primary hepatic or metabolic defect and is virtually pathognomonic for hyperinsulinism.</p><p><b>Calculate glucose requirement.</b> A requirement of &#x0003e;15 mg/kg/min is highly suggestive of HI (normal requirements: neonate 5-8 mg/kg/min; older infant or child 3-5 mg/kg/min).</p><p>Note: Provocative tests with insulin secretagogues may be dangerous and are contraindicated.</p><p><b>Severe disease.</b> In a newborn or young infant with severe disease that appears shortly after birth, the diagnosis of FHI can be based on documentation of inappropriately elevated plasma insulin concentration (&#x0003e;14.4 pmol/L [2 &#x003bc;U/mL]) in the presence of symptomatic hypoglycemia (plasma glucose concentration &#x0003c;2.7 mmol/L [50 mg/dL]).</p><p>Note: (1) "Inappropriately elevated insulin levels" are difficult to define, largely because of marked differences in specificity and <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of commercial insulin assays. The concentrations mentioned here and in the literature must not be taken as hard cutoffs. (2) Pathologic hypoglycemia levels are not defined in any age group, particularly newborns.</p><p><b>Mild disease.</b> In some individuals, particularly those with milder disease appearing after the first few days or weeks of life, fasting plasma insulin concentrations may fluctuate greatly, and the presence of pathologically elevated insulin concentrations may be difficult to demonstrate convincingly. In these individuals, the following surrogate measurements of insulin action can be useful:</p><ul><li class="half_rhythm"><div>Inappropriate hypoketonemia (free fatty acid concentration &#x0003c;1.5 mmol/L)</div></li><li class="half_rhythm"><div>Exaggerated glycemic response to glucagon (&#x0003e;1.7 mmol/L [30 mg/dL] at a time of hypoglycemia)</div></li><li class="half_rhythm"><div>A markedly elevated glucose requirement to prevent hypoglycemia (i.e., exogenous glucose requirements that may exceed 15-20 mg/kg/min [normal: 5-8 mg/kg/min])</div></li></ul></div><div id="hi.Imaging"><h3>Imaging</h3><p>Fluoro-DOPA positron emission tomography (F-DOPA-PET) has been used successfully for the preoperative localization of focal lesions [<a class="bk_pop" href="#hi.REF.otonkoski.2006.13">Otonkoski et al 2006</a>, <a class="bk_pop" href="#hi.REF.mohnike.2008a.65">Mohnike et al 2008a</a>].</p></div><div id="hi.Histology"><h3>Histology</h3><p>Pancreatic beta cells (comprising &#x0003c;2% of all pancreatic cells) synthesize, store, and secrete insulin. Beta cells are located within the islets of Langerhans. Two major pancreatic histologic types ("diffuse" and "focal") have been described in individuals with FHI. A third histologic form ("atypical" or "mosaic") has also been described, although the genetic etiology of this form of FHI has not yet been discovered [<a class="bk_pop" href="#hi.REF.sempoux.2011.3785">Sempoux et al 2011</a>]:</p><ul><li class="half_rhythm"><div><b>Diffuse</b> involvement of beta cells throughout the pancreas. Seen in approximately 60%-70% of individuals, diffuse disease is characterized by essentially normal neonatal pancreatic architecture. All beta cells are affected and many have large nuclei, abundant cytoplasm, and histologic evidence of increased metabolic activity.</div></li><li class="half_rhythm"><div><b>Focal</b> pancreatic adenomatous hyperplasia. Seen in approximately 30%-40% of individuals, focal changes involve a limited region of the pancreas, with the remainder of the tissue being both histologically and functionally normal. A focal lesion is the confluence of apparently normal islets. Focal lesions typically are not macroscopically visible; they differ from true adenomas, which can be identified on gross inspection of the pancreas. Beta cells outside the focal lesion have small nuclei and sparse cytoplasm-histologic evidence that they are suppressed and not actively producing and secreting insulin.</div></li><li class="half_rhythm"><div><b>Mosaic</b> involvement of the pancreatic islets. Pancreatic histology reveals the coexistence of two types of islets: large islets with cytoplasm-rich beta cells and occasional enlarged nuclei alongside shrunken islets with beta cells exhibiting little cytoplasm and small nuclei. Large islets are mostly confined to a few lobules, suggesting that removal of these particular lobules by partial pancreatectomy could result in a cure [<a class="bk_pop" href="#hi.REF.sempoux.2011.3785">Sempoux et al 2011</a>]. The genetic etiology of this form of FHI is not known.</div></li><li class="half_rhythm"><div>Note: With the current availability of imaging and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, diagnosis and management decisions do not require histology. Biopsy is not part of the initial evaluation, and the pancreatic histology is only known if surgical management is warranted.</div></li></ul></div><div id="hi.Prognosis"><h3>Prognosis</h3><p>If medical treatment can be safely maintained, glycemic control usually becomes easier with time, and most individuals treated medically enter clinical remission after several months or years of treatment [<a class="bk_pop" href="#hi.REF.mazoraronovitch.2009.424">Mazor-Aronovitch et al 2009</a>]. It is generally accepted that those individuals who respond well to medical treatment can be treated chronically without undue risk for long-term complications. Long-term follow up of medically treated individuals shows that some eventually develop glucose intolerance, which can be effectively managed with mild dietary restrictions [<a class="bk_pop" href="#hi.REF.mazoraronovitch.2009.424">Mazor-Aronovitch et al 2009</a>].</p></div></div><div id="hi._escape__2_Genetic_Causes_of_Familial"><h2 id="_hi__escape__2_Genetic_Causes_of_Familial_">2. Genetic Causes of Familial Hyperinsulinism</h2><p>Familial hyperinsulinism (FHI) is the most common cause of persistent neonatal hypoglycemia and should be considered in every infant presenting with unexplained hypoglycemia. Pathogenic variants in 14 genes have been associated with FHI (<a class="figpopup" href="/books/NBK1375/table/hi.T.familial_hyperinsulinism_genes_and/?report=objectonly" target="object" rid-figpopup="fighiTfamilialhyperinsulinismgenesand" rid-ob="figobhiTfamilialhyperinsulinismgenesand">Table 2</a>). However, 40% of probands with FHI do not have an identified molecular cause.</p><div id="hi.T.familial_hyperinsulinism_genes_and" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Familial Hyperinsulinism: Genes and Distinguishing Clinical Features</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1375/table/hi.T.familial_hyperinsulinism_genes_and/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hi.T.familial_hyperinsulinism_genes_and_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1,&#x000a0;2</sup></th><th id="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;">% of FHI<br />Attributed to<br />Pathogenic Variants<br />in This Gene</th><th id="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="2" scope="col" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing Clinical Features</th></tr></thead><tbody><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ABCC8</i>&#x000a0;<sup>3</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">40%-45%&#x000a0;<sup>4,&#x000a0;5</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Large for gestational age</div></li><li class="half_rhythm"><div>Severe refractory hypoglycemia in the 1st 48 hrs of life</div></li><li class="half_rhythm"><div>Respond only partially to diet or diazoxide &#x00026; may require pancreatic resection</div></li><li class="half_rhythm"><div>40% have focal form.</div></li><li class="half_rhythm"><div>Diabetes may develop later in life.</div></li><li class="half_rhythm"><div>Founder variants in <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> &#x00026; Finnish populations&#x000a0;<sup>6</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Appropriate for gestational age at birth</div></li><li class="half_rhythm"><div>Present at age ~1 yr (range: 2 days &#x02013; 30 yrs)</div></li><li class="half_rhythm"><div>Respond to diet &#x00026; diazoxide therapy, exceptions reported</div></li><li class="half_rhythm"><div>Variable <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a></div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CACNA1D</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 individual&#x000a0;<sup>7</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Persistent diazoxide-responsive hypoglycemia</div></li><li class="half_rhythm"><div>Mild aortic insufficiency</div></li><li class="half_rhythm"><div>Severe hypotonia &#x00026; developmental delay</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GCK</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%&#x000a0;<sup>8</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ranges from mild diazoxide-responsive hypoglycemia to severe, diazoxide-unresponsive hypoglycemia.</div></li><li class="half_rhythm"><div>Insulin secretion in response to elevation &#x00026; suppression of glucose levels is qualitatively normal, but the glucose set-point at which insulin secretion is turned off is abnormally low.</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GLUD1</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%&#x000a0;<sup>9</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperammonemia/hyperinsulinism syndrome
<ul><li class="half_rhythm"><div>Mild-to-moderate hyperammonemia (1.5-4.0 times the upper limit of normal)</div></li><li class="half_rhythm"><div>Ammonia levels are not related to ambient glucose levels or to duration of fasting &#x00026; appear to be benign.</div></li><li class="half_rhythm"><div>Mild hypoglycemia usually presents after neonatal period.</div></li><li class="half_rhythm"><div>May be associated with exquisite sensitivity to leucine challenge</div></li><li class="half_rhythm"><div>Most respond well to diazoxide; only a minority require surgery to prevent recurrent hypoglycemia.</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HADH</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%&#x000a0;<sup>10,&#x000a0;11</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>&#x02191; urine 3-hydroxyglutaric acid &#x00026; serum 3-hydroxybutyryl-carnitine</div></li><li class="half_rhythm"><div>Severe hypoglycemia after leucine administration</div></li><li class="half_rhythm"><div>Mild diazoxide-responsive hypoglycemia; severe hypoglycemia has been reported.</div></li><li class="half_rhythm"><div>Normal urinary 3-hydoxyglutaric acid &#x00026; a normal plasma acylcarnitine profile does not exclude the diagnosis.</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HK1</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 family&#x000a0;<sup>12</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Diagnosed w/FHI before age 1 yr</div></li><li class="half_rhythm"><div>40% presented w/a seizure</div></li><li class="half_rhythm"><div>Diazoxide responsive</div></li><li class="half_rhythm"><div>Failed to adequately suppress insulin secretion following oral glucose tolerance test or prolonged fasting</div></li><li class="half_rhythm"><div>Not leucine sensitive</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HNF1A</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Large for gestational age</div></li><li class="half_rhythm"><div>Mild diazoxide-sensitive hypoglycemia</div></li><li class="half_rhythm"><div>Hypoglycemia usually resolves in childhood.</div></li><li class="half_rhythm"><div>MODY3 develops in adolescence or adulthood.</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HNF4A</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%&#x000a0;<sup>13</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Large for gestational age</div></li><li class="half_rhythm"><div>Mild diazoxide-sensitive hypoglycemia</div></li><li class="half_rhythm"><div>Hypoglycemia sometimes transient</div></li><li class="half_rhythm"><div>Insulinopenic diabetes mellitus during adolescence</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PMM2</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11 families&#x000a0;<sup>14</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Associated w/polycystic kidney disease in all individuals</div></li><li class="half_rhythm"><div>~50% also have hepatic cysts.</div></li><li class="half_rhythm"><div>Diazoxide responsive</div></li><li class="half_rhythm"><div>Associated w/late-infantile seizures w/out neurologic damage</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>KCNJ11</i>&#x000a0;<sup>3</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">5%&#x000a0;<sup>15</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Large for gestational age</div></li><li class="half_rhythm"><div>Severe refractory hypoglycemia in the 1st 48 hrs of life</div></li><li class="half_rhythm"><div>Affected infants usually respond only partially to diet or diazoxide therapy; may require pancreatic resection.</div></li><li class="half_rhythm"><div>40% have focal form.</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Appropriate for gestational age at birth</div></li><li class="half_rhythm"><div>Present at age ~1 yr (range: 2 days &#x02013; 30 yrs)</div></li><li class="half_rhythm"><div>Respond to diet &#x00026; diazoxide therapy, exceptions reported</div></li><li class="half_rhythm"><div>Variable <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a></div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC16A1</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hypoglycemia occurs during childhood or later.</div></li><li class="half_rhythm"><div>Severe hypoglycemia occurring after anaerobic &#x00026; not aerobic exercise</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>UCP2</i></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2% of diazoxide-responsive HI&#x000a0;<sup>16</sup></td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Mild diazoxide-responsive hypoglycemia</div></li><li class="half_rhythm"><div>Children reported w/hypoglycemia 4 hrs after glucose intake</div></li><li class="half_rhythm"><div>Recently questioned as a monogenic cause of hypoglycemia&#x000a0;<sup>17</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_hi.T.familial_hyperinsulinism_genes_and_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hi.TF.2.1"><p class="no_margin">Genes are listed alphabetically.</p></div></dd><dt>2. </dt><dd><div id="hi.TF.2.2"><p class="no_margin">See <a href="/books/NBK1375/#hi.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>3. </dt><dd><div id="hi.TF.2.3"><p class="no_margin"><i>ABCC8</i>- and <i>KCNJ11</i>-related FHI are also known as FHI-K<sub>ATP</sub><sup>.</sup></p></div></dd><dt>4. </dt><dd><div id="hi.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#hi.REF.nestorowicz.1998.1119">Nestorowicz et al [1998]</a>, <a class="bk_pop" href="#hi.REF.aguilarbryan.1999.101">Aguilar-Bryan &#x00026; Bryan [1999]</a>, <a class="bk_pop" href="#hi.REF.meissner.1999.351">Meissner et al [1999]</a>, <a class="bk_pop" href="#hi.REF.fournet.2003.30">Fournet &#x00026; Junien [2003]</a>, <a class="bk_pop" href="#hi.REF.tornovsky.2004.6224">Tornovsky et al [2004]</a></p></div></dd><dt>5. </dt><dd><div id="hi.TF.2.5"><p class="no_margin">A few <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or multiexon deletions have been reported in <i>ABCC8</i> (see <a href="/books/NBK1375/#hi.molgen.TA">Table A</a>).</p></div></dd><dt>6. </dt><dd><div id="hi.TF.2.6"><p class="no_margin">In the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population, two <i>ABCC8</i> founder variants, p.Phe1387del and c.3989-9G&#x0003e;A, are responsible for approximately 97% of FHI [<a class="bk_pop" href="#hi.REF.glaser.2011.891">Glaser et al 2011</a>]. <i>ABCC8</i> founder variants present in the Finnish population include p.Val187Asp and p.Glu1506Lys [<a class="bk_pop" href="#hi.REF.otonkoski.1999.408">Otonkoski et al 1999</a>, <a class="bk_pop" href="#hi.REF.huopio.2000.897">Huopio et al 2000</a>].</p></div></dd><dt>7. </dt><dd><div id="hi.TF.2.7"><p class="no_margin"><a class="bk_pop" href="#hi.REF.flanagan.2017.320">Flanagan et al [2017]</a></p></div></dd><dt>8. </dt><dd><div id="hi.TF.2.8"><p class="no_margin"><a class="bk_pop" href="#hi.REF.glaser.1998.226">Glaser et al [1998]</a>, <a class="bk_pop" href="#hi.REF.christesen.2002.1240">Christesen et al [2002]</a>, <a class="bk_pop" href="#hi.REF.cuestamu_oz.2004.2164">Cuesta-Mu&#x000f1;oz et al [2004]</a>, <a class="bk_pop" href="#hi.REF.sayed.2009.1419">Sayed et al [2009]</a></p></div></dd><dt>9. </dt><dd><div id="hi.TF.2.9"><p class="no_margin"><a class="bk_pop" href="#hi.REF.stanley.2000.667">Stanley et al [2000]</a>, <a class="bk_pop" href="#hi.REF.bahibuisson.2008.945">Bahi-Buisson et al [2008]</a></p></div></dd><dt>10. </dt><dd><div id="hi.TF.2.10"><p class="no_margin"><a class="bk_pop" href="#hi.REF.clayton.2001.457">Clayton et al [2001]</a>, <a class="bk_pop" href="#hi.REF.molven.2004.221">Molven et al [2004]</a>, <a class="bk_pop" href="#hi.REF.di_candia.2009.1019">Di Candia et al [2009]</a></p></div></dd><dt>11. </dt><dd><div id="hi.TF.2.11"><p class="no_margin">Rare large deletions including <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 have been reported [<a class="bk_pop" href="#hi.REF.flanagan.2011.e498">Flanagan et al 2011</a>].</p></div></dd><dt>12. </dt><dd><div id="hi.TF.2.12"><p class="no_margin"><a class="bk_pop" href="#hi.REF.pinney.2013.18">Pinney et al [2013]</a></p></div></dd><dt>13. </dt><dd><div id="hi.TF.2.13"><p class="no_margin"><a class="bk_pop" href="#hi.REF.flanagan.2010.987">Flanagan et al [2010]</a></p></div></dd><dt>14. </dt><dd><div id="hi.TF.2.14"><p class="no_margin"><a class="bk_pop" href="#hi.REF.cabezas.2017.2529">Cabezas et al [2017]</a></p></div></dd><dt>15. </dt><dd><div id="hi.TF.2.15"><p class="no_margin"><a class="bk_pop" href="#hi.REF.thomas.1996.1809">Thomas et al [1996]</a>, <a class="bk_pop" href="#hi.REF.nestorowicz.1997.1743">Nestorowicz et al [1997]</a>, <a class="bk_pop" href="#hi.REF.tornovsky.2004.6224">Tornovsky et al [2004]</a></p></div></dd><dt>16. </dt><dd><div id="hi.TF.2.16"><p class="no_margin"><a class="bk_pop" href="#hi.REF.ferrara.2017.942">Ferrara et al [2017]</a> have recently shown variable <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> by age with children developing post-glucose-challenge hypoglycemia.</p></div></dd><dt>17. </dt><dd><div id="hi.TF.2.17"><p class="no_margin"><a class="bk_pop" href="#hi.REF.laver.2017.1442">Laver et al [2017]</a> claim, based on studies including large numbers of variants in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, that the variants may act as low-effect risk factors, and that <i>in vitro</i> evidence of a role in insulin secretion for this protein is not proof of monogenic disease.</p></div></dd></dl></div></div></div><div id="hi.Other_Disorders_to_Consider_in_the_Di"><h3>Other Disorders to Consider in the Differential Diagnosis of Familial Hyperinsulinism</h3><p>Hyperinsulinemic hypoglycemia can be seen in disorders other than FHI. Furthermore, neonatal hypoglycemia can be caused by non-insulin-mediated mechanisms, in which case plasma insulin concentrations are low and plasma glucose concentrations can be readily corrected with normal replacement doses of glucose (5-8 mg/kg/min).</p><div id="hi.T._escape_other_disorders_to_consider" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Other Disorders to Consider in the Differential Diagnosis of Familial Hyperinsulinism (FHI)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1375/table/hi.T._escape_other_disorders_to_consider/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hi.T._escape_other_disorders_to_consider_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s) or Locus</th><th id="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of the Disorder Distinguishing from FHI</th></tr></thead><tbody><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1 hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2 hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3 hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" colspan="4" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Hyperinsulinemic hypoglycemia</b></td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infants of diabetic mother</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypoglycemia is transient, resolving w/in days to wks after birth.</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Transient hyperinsulinemic hypoglycemia of infancy</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Typically responds well to diazoxide therapy</div></li><li class="half_rhythm"><div>May occur after history of perinatal stress or asphyxia</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/bws/">Beckwith-Wiedemann syndrome</a></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CDKN1C</i><br />11p15</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD or <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically mild &#x00026; responds to medical treatment w/diazoxide</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Familial hyperinsulinemic hypoglycemia type 5 (OMIM <a href="https://omim.org/entry/609968" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609968</a>)</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>INSR</i></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Postprandial hypoglycemia occurs 3-5 hrs after meals.</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>INSR</i>-related severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> insulin resistance&#x000a0;<sup>1</sup></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>INSR</i></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fasting hypoglycemia associated w/insulin resistance syndrome</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Insulinoma<br />(<a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> or due to <a href="/books/n/gene/men1/">multiple endocrine neoplasia type 1</a>)</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MEN1</i></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD or <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Onset typically age &#x0003e;1 yr</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1 hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2 hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3 hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" colspan="4" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Hypoglycemia w/out hypersinulinemia</b></td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cah/">21-hydroxylase-deficient congenital adrenal hyperplasia</a></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CYP21A2</i></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Typically ketotic hypoglycemia, suppressed plasma insulin levels, &#x00026; blunted glycemic response to glucagon. Hypoglycemia typically mild</div></li><li class="half_rhythm"><div>Congenital deficiency of cortisol</div></li><li class="half_rhythm"><div>Responds to steroid therapy</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ahc/"><i>NR0B1</i>-related adrenal hypoplasia congenita</a></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NR0B1</i></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Primary adrenal insufficiency</div></li><li class="half_rhythm"><div>Hypogonadotropic hypogonadism</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pituitary hormone deficiencies (OMIM <a href="https://omim.org/phenotypicSeries/PS613038" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS613038</a>)</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hypoglycemia typically mild</div></li><li class="half_rhythm"><div>Responds to growth hormone</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Glycogen storage diseases (see <a href="/books/n/gene/gsd1/">Glycogen Storage Disease Type I</a>)</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />XL</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fasting hypoglycemia</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gluconeogenesis disorders (see fructose 1,6-diphosphatase deficiency, OMIM <a href="http://www.omim.org/entry/229700" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">229700</a>)</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypoglycemia primarily during fasting or intercurrent illness w/lactic acidosis</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1 hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2 hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3 hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" colspan="4" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Hyperammonemia/hyperinsulinism</b></td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorders of fatty acid oxidation (see <a href="/books/n/gene/mcad/">MCAD deficiency</a>)</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />AD<br />XL</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Fasting hypoketotic hypoglycemia</div></li><li class="half_rhythm"><div>Myopathy &#x00026;/or cardiomyopathy</div></li><li class="half_rhythm"><div>Acute symptoms precipitated by fasting or acute illness</div></li><li class="half_rhythm"><div>Acylcarnitine profile on tandem mass spectrometry may be diagnostic.</div></li></ul>
</td></tr><tr><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ucd-overview/">Urea cycle disorders</a></td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />XL</td><td headers="hd_h_hi.T._escape_other_disorders_to_consider_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hyperammonemia</div></li><li class="half_rhythm"><div>Absence of hyperinsulinism</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; NA = not applicable; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="hi.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#hi.REF.ben_abdelaziz.2016.16">Ben Abdelaziz et al [2016]</a></p></div></dd></dl></div></div></div></div></div><div id="hi._escape__3_Evaluation_Strategies_to_I"><h2 id="_hi__escape__3_Evaluation_Strategies_to_I_">3. Evaluation Strategies to Identify the Genetic Cause of Familial Hyperinsulinism in a Proband</h2><p>Establishing a specific genetic cause of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hyperinsulinism (FHI):</p><ul><li class="half_rhythm"><div>Can aid in discussions of prognosis (which are beyond the scope of this <i>GeneReview</i>) and <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>;</div></li><li class="half_rhythm"><div>Usually involves a medical history, physical examination, laboratory testing, family history, and <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a>/genetic testing.</div></li></ul><p><b>Medical history.</b> There are few points in the history that can help differentiate specific genetic causes of FHI. However, ethnic background can increase the probability of some forms (e.g., <i>ABCC8</i> <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> individuals). Hypoglycemia occurring postprandially, particularly after protein-rich meals, with relatively stable overnight glycemia may suggest a <i>GLUD1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. A robust response to a low dose of diazoxide is unusual in individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ABCC8</i> or <i>KCNJ11</i> pathogenic variants but typical of most other types of FHI. See <a class="figpopup" href="/books/NBK1375/table/hi.T.familial_hyperinsulinism_genes_and/?report=objectonly" target="object" rid-figpopup="fighiTfamilialhyperinsulinismgenesand" rid-ob="figobhiTfamilialhyperinsulinismgenesand">Table 2</a> for additional findings that may suggest specific types of FHI. A history of severe hypoglycemia occurring after anaerobic exercise is suggestive of FHI type 7 (see <a class="figpopup" href="/books/NBK1375/table/hi.T._escape_other_disorders_to_consider/?report=objectonly" target="object" rid-figpopup="fighiTescapeotherdisorderstoconsider" rid-ob="figobhiTescapeotherdisorderstoconsider">Table 3</a>).</p><p><b>Physical examination.</b> There are no phenotypic findings on physical examination that can differentiate the different genetic causes of FHI.</p><p><b>Family history.</b> A three-generation family history should be taken, with attention to relatives with manifestations of FHI and documentation of relevant findings through direct examination or review of medical records, including results of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p><b>Molecular genetic testing</b> approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> or single-gene testing) and <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>). Gene-targeted testing requires the clinician to hypothesize which gene(s) are likely involved, whereas genomic testing does not.</p><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes some or all of the genes listed in <a class="figpopup" href="/books/NBK1375/table/hi.T.familial_hyperinsulinism_genes_and/?report=objectonly" target="object" rid-figpopup="fighiTfamilialhyperinsulinismgenesand" rid-ob="figobhiTfamilialhyperinsulinismgenesand">Table 2</a> is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> can be considered if clinical findings and/or family history indicate that pathogenic variants in a particular gene are most likely (see <a class="figpopup" href="/books/NBK1375/table/hi.T.familial_hyperinsulinism_genes_and/?report=objectonly" target="object" rid-figpopup="fighiTfamilialhyperinsulinismgenesand" rid-ob="figobhiTfamilialhyperinsulinismgenesand">Table 2</a>).</p><ul><li class="half_rhythm"><div>Individuals of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> descent: <i>ABCC8</i> pathogenic founder variants</div><ul><li class="half_rhythm"><div>p.Phe1387del</div></li><li class="half_rhythm"><div>c.3989-9G&#x0003e;A</div></li></ul></li><li class="half_rhythm"><div>Individuals of Finnish heritage: <i>ABCC8</i> pathogenic founder variants</div><ul><li class="half_rhythm"><div>p.Val187Asp</div></li><li class="half_rhythm"><div>p.Glu1506Lys</div></li></ul></li><li class="half_rhythm"><div>Individuals with elevated serum ammonia: <i>GLUD1</i> pathogenic variants. Note: Sequencing of exons 6, 7, 10, 11, and 12 identifies virtually all pathogenic variants in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, although it is possible that causative variants occur in other exons as well.</div></li></ul><p><b>Comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) may be considered. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p></div><div id="hi._escape__4_Medical_Management_of_FHI"><h2 id="_hi__escape__4_Medical_Management_of_FHI_">4. Medical Management of FHI Based on Genetic Cause</h2><div id="hi.Initial_Treatment"><h3>Initial Treatment</h3><p>Once initial diagnostic blood samples are obtained, the hypoglycemia must be corrected immediately using intravenous glucose at a dose sufficient to prevent further hypoglycemia and irreversible brain damage. The dose of glucose may be high (&#x0003e;15 mg/kg/min) and frequently requires central venous access. The definition of adequate glucose control has been the subject of discussion. Most investigators recommend maintaining all glucose levels &#x0003e;3.3 mmol/L (60 mg/dL), a level that leaves a sufficient margin to prevent frequent episodes of neuroglycopenia (i.e., transient or permanent brain dysfunction caused by inadequate glucose supplies) [<a class="bk_pop" href="#hi.REF.burns.2008.65">Burns et al 2008</a>, <a class="bk_pop" href="#hi.REF.inder.2008.440">Inder 2008</a>].</p></div><div id="hi.LongTerm_Medical_Management"><h3>Long-Term Medical Management</h3><p>The next phase of treatment, designed to decrease and eliminate parenteral glucose requirement, is empiric and involves a combination of medical therapies. Some individuals, particularly those with <i>GLUD1</i>-, <i>HADH</i>-, or <i>GCK</i>-related FHI or dominant pathogenic variants in either <i>ABCC8</i> or <i>KCNJ11</i>, respond very well to medical therapy. Individuals with severe FHI-K<sub>ATP</sub> (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> pathogenic variants in <i>ABCC8</i> or <i>KCNJ11</i>) may also respond to medical therapy; however, these individuals often require aggressive medical management, including a combination of several of the drugs mentioned below along with dietary intervention (that may even require the use of frequent gastrostomy feeds for several years) to maintain plasma glucose concentration in a clinically safe range without the use of parenteral glucose administration. This management protocol may be extremely demanding and, even if successful in the hospital setting, may not be appropriate for many families on an outpatient basis. The overall success of medical management in FHI-K<sub>ATP</sub> is extremely variable [<a class="bk_pop" href="#hi.REF.mazoraronovitch.2009.424">Mazor-Aronovitch et al 2009</a>].</p><ul><li class="half_rhythm"><div><b>Diazoxide,</b> which binds to the ABCC8 subunit of the K<sub>ATP</sub> channel, increases the channel's probability of being open, resulting in membrane hyperpolarization and inhibition of insulin release. Some evidence suggests that diazoxide binding to mutated channels may correct abnormal protein folding and thus facilitate the transit of more channels to the membrane. The effective therapeutic dose varies but may be as high as 20 mg/kg/day in divided doses. A thiazide diuretic should be given along with diazoxide with doses &#x0003e;8-10 mg/kg/day to prevent fluid retention, which may be severe [<a class="bk_pop" href="#hi.REF.hussain.2004.163">Hussain et al 2004</a>].</div></li><li class="half_rhythm"><div><b>Somatostatin analogs</b> (e.g., octreotide or lanreotide) suppress insulin secretion by binding to specific beta-cell receptors and initiating a number of intracellular signaling pathways. The clinical efficacy of octreotide may be limited by the relatively short duration of inhibition of insulin secretion after subcutaneous bolus injection (~3 hours) and by the fact that these drugs also inhibit glucagon and growth hormone secretion, thus impairing hepatic glucose production. Careful attention to dosage (typically 10-15 &#x003bc;g/kg/day for octreotide) as well as the use of continuous subcutaneous injection using a portable pump greatly enhances clinical efficacy [<a class="bk_pop" href="#hi.REF.hussain.2004.163">Hussain et al 2004</a>]. Simultaneous treatment with glucagon may enhance efficacy. Long-acting analogs including LAR octreotide [<a class="bk_pop" href="#hi.REF.le_quan_sang.2012.333">Le Quan Sang et al 2012</a>] and lanreotide [<a class="bk_pop" href="#hi.REF.modanmoses.2011.2312">Modan-Moses et al 2011</a>] can be used after the hypoglycemia becomes manageable and stable, usually after age three to four years.</div></li><li class="half_rhythm"><div><b>Nifedipine,</b> which acts as an inhibitor of the voltage-dependent calcium channels present in the beta cell, inhibits insulin secretion by decreasing calcium influx [<a class="bk_pop" href="#hi.REF.hussain.2004.163">Hussain et al 2004</a>]. In vitro, this drug effectively suppresses insulin secretion depending on the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; however, in vivo side effects are usually dose limiting, and the drug is only rarely clinically effective.</div></li><li class="half_rhythm"><div><b>Glucagon,</b> which increases hepatic gluconeogenesis, helps prevent hypoglycemia. The drug can be used acutely to treat severe hypoglycemia, or chronically as replacement therapy to counteract suppression by somatostatin analogs, but this therapy is hampered by crystallization of the glucagon in continuous subcutaneous infusion sets [<a class="bk_pop" href="#hi.REF.mohnike.2008b.59">Mohnike et al 2008b</a>].</div></li><li class="half_rhythm"><div><b>Recombinant IGF-I</b> has been shown to suppress insulin secretion in individuals with FHI [<a class="bk_pop" href="#hi.REF.katz.1999.3117">Katz et al 1999</a>]; however, therapeutic success has not been confirmed.</div></li><li class="half_rhythm"><div><b>Glucocorticoids</b> induce resistance to endogenous insulin and correct the inadequate cortisol response sometimes seen in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Their use in the treatment algorithm of FHI is, however, very limited.</div></li><li class="half_rhythm"><div><b>Growth hormone</b> may be given in combination with somatostatin analogs in order to counteract growth hormone suppression by the analogs. However, this is rarely needed as the dose of somatostatin analogs is usually reduced during childhood as the condition improves, so that growth suppression is not a significant clinical issue.</div></li><li class="half_rhythm"><div><b>Dietary intervention</b></div><ul><li class="half_rhythm"><div>Frequent high-carbohydrate feedings, including formula supplemented with glucose polymer</div></li><li class="half_rhythm"><div>Nighttime continuous gastric drip containing glucose or glucose polymer</div></li><li class="half_rhythm"><div>Feeding gastrostomy to simplify the process of continuous nighttime feeding and to provide access for emergency home treatment of hypoglycemia</div></li></ul></li></ul></div><div id="hi.Surgical_Management"><h3>Surgical Management</h3><p>Once an individual is stabilized, a decision must be made as to the need for surgical intervention and the extent of such intervention. In some severe cases, even the most aggressive medical management fails to maintain plasma glucose concentration consistently within the safe limits (&#x0003e;60 mg/dL). In such individuals, surgery must be considered. Prior to surgical intervention, differentiation between focal and diffuse disease using one of the following techniques is important, as the surgical approach and the clinical outcome are quite different:</p><ul><li class="half_rhythm"><div><b>Genetic studies,</b> in certain circumstances, can be useful in differentiating focal from diffuse disease:</div><ul><li class="half_rhythm"><div class="half_rhythm">Finding two recessive pathogenic variants or a single dominant <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is diagnostic of diffuse disease.</div></li><li class="half_rhythm"><div class="half_rhythm">Finding a single recessive <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on the maternal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> suggests diffuse disease; it is assumed that the other pathogenic variant on the paternal allele was missed because of technical limitations of the <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">Finding a single recessive <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on the paternal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is consistent with and highly suggestive of focal disease, although it cannot be considered diagnostic, as <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> methods could have failed to detect a pathogenic variant on the maternal allele. In such individuals, further testing to diagnose and localize focal disease is indicated.</div><div class="half_rhythm">Because of the large size of <i>ABCC8</i> and <i>KNCJ11</i>, complete sequencing and analysis of all variants discovered is expensive and time-consuming and may not be completed in time to aid in clinical decision making for a severely ill individual. With the incorporation of modern sequencing techniques, rapid complete sequencing of all relevant genes is becoming feasible. In contrast, for a person from an ethnic group with a known <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> (e.g., Ashkenazi Jews), <a class="def" href="/books/n/gene/glossary/def-item/targeted-analysis-for-pathogenic-variants/">targeted analysis for pathogenic variants</a> can provide rapid and inexpensive clinically useful information.</div></li></ul></li><li class="half_rhythm"><div><b>Fluoro-DOPA positron emission tomography (F-DOPA-PET)</b> has been used successfully for the preoperative localization of focal lesions [<a class="bk_pop" href="#hi.REF.otonkoski.2006.13">Otonkoski et al 2006</a>, <a class="bk_pop" href="#hi.REF.mohnike.2008a.65">Mohnike et al 2008a</a>] (see <a href="#hi.Clinical_Manifestations">Clinical Manifestations</a>). While the scan itself is relatively easy to perform, the radiopharmaceutical is not readily available in many centers and the scan can be difficult to interpret, requiring extensive experience to obtain reliable results.</div></li><li class="half_rhythm"><div><b>Intraoperative histologic evaluation of a pancreatic biopsy</b> in very experienced hands can be used to differentiate between diffuse FHI and a normal, suppressed pancreas in an individual with a focal lesion. Since intraoperative identification of the focal lesion can be very difficult or impossible, resection of the lesion is usually only possible if its location is determined preoperatively.</div></li></ul><p>Individuals with diffuse disease require extensive (80%-95%) pancreatic resection and are at risk for persistent hypoglycemia postoperatively and/or insulin-requiring diabetes mellitus later in childhood. Individuals with focal disease can be cured by localized resection of the hyperplastic region. Although the apparent risk for postoperative diabetes appears to be very low after limited pancreatectomy, very long-term follow up is not yet available on these individuals [<a class="bk_pop" href="#hi.REF.beltrand.2012.198">Beltrand et al 2012</a>]. Since focal lesions can only rarely be identified grossly at the time of surgery, perioperative diagnosis and localization of focal lesions is needed.</p></div><div id="hi.Surveillance"><h3>Surveillance</h3><p>In persons with clinically mild disease, episodes of subtle, undiagnosed hypoglycemia can cause permanent brain damage. Therefore, close monitoring and vigilance is just as critical in mild cases as it is in severe cases. Furthermore, in persons with mild disease and in those with severe disease in clinical remission, severe hypoglycemia may be precipitated by intercurrent viral illness. Thus, it is imperative that parents monitor glucose concentrations closely especially during intercurrent illness, even in the absence of symptomatic hypoglycemia. Identification of the genetic cause of FHI can help guide the frequency of blood glucose testing. Individuals who are diazoxide responsive and take their medication regularly will need less frequent glucose monitoring than non-diazoxide-responsive individuals. In the first few years of life, use of continuous glucose monitoring is recommended for children with very unstable glucose levels regardless of the genetic cause.</p></div><div id="hi.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Prolonged fasting of any sort should be avoided. Emergency treatment options for hypoglycemia must be available at all times in case of an unexpected hypoglycemic episode.</p></div><div id="hi.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Affected individuals who previously underwent near-total or sub-total pancreatectomy typically have insulin-requiring diabetes by the time they become pregnant. In this case, treatment is the same as for individuals with preexisting diabetes from any cause. There is little, if any, experience with pregnancy in individuals who were treated conservatively or who underwent limited pancreatectomy for focal FHI, as these treatments are relatively new. In this situation, close monitoring of glucose to detect both recurrent hypoglycemia and hyperglycemia is warranted. If hyperglycemia is documented, treatment should be instituted as for any woman with gestational diabetes. A fetus at risk for FHI should be monitored for size and weight. Excessive fetal weight gain during the last trimester of pregnancy increases the risk of obstetric complications and of cesarean delivery. In pregnant women with a history of FHI and gestational hyperglycemia due to prior surgical treatment, the fetus should be monitored as for any case of preexisting type 1, preexisting type 2, or gestational diabetes.</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div></div><div id="hi._escape__5_Risk_Assessment_and_Survei"><h2 id="_hi__escape__5_Risk_Assessment_and_Survei_">5. Risk Assessment and Surveillance of At-Risk Relatives for Early Detection and Treatment of FHI</h2><div id="hi.Genetic_Risk_Assessment"><h3>Genetic Risk Assessment</h3><p>Familial hyperinsulinism (FHI) can be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><ul><li class="half_rhythm"><div>FHI-K<sub>ATP</sub>, caused by pathogenic variants in either <i>ABCC8</i> or <i>KCNJ11</i>, is most commonly inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner, and rarely in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</div></li><li class="half_rhythm"><div>FHI-CACNA1D, FHI-GCK, FHI-GLUD1, FHI-HK1, FHI-HNF1A, FHI-HNF4A, and FHI-UCP2 are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</div></li><li class="half_rhythm"><div>FHI-HADH and FHI-PMM2 are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</div></li><li class="half_rhythm"><div>The focal form of FHI is caused by pathogenic variants in <i>ABCC8</i> or <i>KCNJ11</i> and is inherited in what can be defined, officially, as an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner; however, the focal form of FHI is associated with markedly reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> and is a biologically low-risk occurrence among individuals who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a paternal <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul></div><div id="hi.Autosomal_Recessive_Inheritance"><h3>Autosomal Recessive Inheritance</h3><div id="hi.Risk_to_Family_Members"><h4>Risk to Family Members</h4><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are typically asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, and a 25% chance of being unaffected and not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</div></li><li class="half_rhythm"><div>Sibs <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a paternally derived <i>ABCC8</i> or <i>KCNJ11</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at a 1:540 risk for focal FHI (see <a href="#hi.Autosomal_Dominant_Inheritance_Focal">AD Focal Form &#x02013; Risk to Family Members</a>, <b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b>) [<a class="bk_pop" href="#hi.REF.glaser.2011.891">Glaser et al 2011</a>]. This risk is expected to be independent of the specific pathogenic variant involved [<a class="bk_pop" href="#hi.REF.glaser.2011.891">Glaser et al 2011</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> FHI are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div><div class="half_rhythm">Heterozygous offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are at risk of developing focal FHI (see <a href="#hi.Autosomal_Dominant_Inheritance_Focal">AD Focal Form &#x02013; Risk to Family Members</a>, <b>Offspring of a proband</b>).</div></li><li class="half_rhythm"><div class="half_rhythm">The risk to offspring of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> FHI depends on the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency in the reproductive partner's ethnic group. In most cases, the carrier frequency appears to be approximately 1% or less; however, genetic isolates with very high carrier frequency have been reported. In Ashkenazi Jews, for example, the <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> is estimated at 1:52; the risk to the child of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and an individual of <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> heritage would be approximately 1:104, or 1% [<a class="bk_pop" href="#hi.REF.glaser.2011.891">Glaser et al 2011</a>].</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="hi.Carrier_Heterozygote_Detection"><h4>Carrier (Heterozygote) Detection</h4><p>Carrier testing for at-risk relatives requires prior identification of the pathogenic variants in the family.</p></div></div><div id="hi.Autosomal_Dominant_Inheritance_Diffus"><h3>Autosomal Dominant Inheritance, Diffuse Form &#x02013; Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>One of the parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child may be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and thus be affected by FHI.</div></li><li class="half_rhythm"><div>More typically, a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with HI has the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div><ul><li class="half_rhythm"><div>The proportion of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants is estimated at approximately 75% for HA/HI.</div></li><li class="half_rhythm"><div>Neither of the two families with FHI-GCK reported by <a class="bk_pop" href="#hi.REF.glaser.1998.226">Glaser et al [1998]</a> or <a class="bk_pop" href="#hi.REF.christesen.2002.1240">Christesen et al [2002]</a> were <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s generation. However, <a class="bk_pop" href="#hi.REF.cuestamu_oz.2004.2164">Cuesta-Mu&#x000f1;oz et al [2004]</a> and Martinez el al [2017] each reported <i>de novo</i> activating <i>GCK</i> pathogenic variants that resulted in severe hyperinsulinemia in female infants.</div></li></ul></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, and, if positive, clinical testing for fasting and postprandial hypoglycemia.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Though theoretically possible, no instances of germline mosaicism have been reported.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> FHI may appear to be negative because of failure to recognize the disorder in family members, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the clinical/genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or is known to have the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is estimated to be 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#hi.REF.rahbari.2016.126">Rahbari et al 2016</a>].</div></li><li class="half_rhythm"><div>If the parents have not been tested for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low. However, sibs of a proband with clinically unaffected parents are still presumed to be at increased risk for FHI because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent or the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with FHI has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or has the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members are at risk.</p></div><div id="hi.Autosomal_Dominant_Inheritance_Focal"><h3>Autosomal Dominant Inheritance, Focal Form &#x02013; Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The fathers of individuals with focal FHI are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ABCC8</i> or <i>KCNJ11</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Given the low risk for a person with such a variant of having focal disease (estimated at 1:540 due to a somatic loss of maternal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in a single cell [<a class="bk_pop" href="#hi.REF.glaser.2011.891">Glaser et al 2011</a>]), the chance that both father and child will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> is less than 1:250,000. Thus, for practical purposes the fathers do not have focal FHI. The pathogenic variants responsible for <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> diffuse FHI are not associated with focal HI.</div></li><li class="half_rhythm"><div>Although no instances of focal FHI caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on the paternally derived <i>ABCC8</i> or <i>KCNJ11</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> have been reported, it remains a possibility.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with focal FHI have a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from their father. However, the focal form of FHI manifests only when the pathogenic variant occurs on the paternally derived <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and a separate, independent somatic event results in the loss of the maternal allele (<a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a>).</div></li><li class="half_rhythm"><div>The risk for focal FHI in a sib of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has been estimated at 1:540 [<a class="bk_pop" href="#hi.REF.glaser.2011.891">Glaser et al 2011</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with focal FHI has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>The risk to offspring of having the diffuse form of hyperinsulinemia is related to the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency in the reproductive partner's ethnic group, as offspring will have this form of hyperinsulinemia only if they inherit a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from both parents.</div></li><li class="half_rhythm"><div>Each child of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with focal FHI is also at risk of developing focal FHI. To develop FHI, the individual must inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from the father (50% chance) and a second somatic event must occur, the latter being quite uncommon. The estimated risk for focal FHI to the offspring of a male proband with focal FHI is 1:540 [<a class="bk_pop" href="#hi.REF.glaser.2011.891">Glaser et al 2011</a>].</div></li></ul><p><b>Other family members.</b> The sibs of the father of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with focal FHI may also carry an <i>ABCC8</i> or <i>KCNJ11</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. However, the focal form of FHI manifests only when the pathogenic variant occurs on the paternally derived <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and a somatic event resulting in the loss of the maternal allele occurs (<a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a>).</p></div><div id="hi.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the clinical/genetic status of sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual so that appropriate evaluation and treatment can be initiated before hypoglycemia occurs. Because of the severe neurologic consequences of delayed diagnosis and treatment, it is imperative that at-risk newborns be followed closely from birth and a definitive diagnosis made as rapidly as possible.</p><p>Evaluations can include the following:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family are known. (Note: If the causative pathogenic variants have been identified in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, it is prudent to test all at-risk relatives; depending on the findings, more extensive family investigations may be warranted.)</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known, careful glucose monitoring of newborns thought to be at risk based on the inheritance pattern should be undertaken and parents should be aware of signs of hypoglycemia that would require investigation during childhood.</div></li></ul><p>See <a href="#hi.Related_Genetic_Counseling_Issues">Related Genetic Counseling Issues</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hi.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Mode of inheritance when no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified.</b> Approximately 40% of individuals with HI do not have an identifiable pathogenic variant in any of the genes known to be associated with HI. Risk to family members in these families is not known.</p><p><b>Family planning &#x02013; <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li><li class="half_rhythm"><div>Because of the relatively high prevalence of two specific <i>ABCC8</i> pathogenic variants in the <a class="def" href="/books/n/gene/glossary/def-item/ashkenazi-jewish/">Ashkenazi Jewish</a> population, preconception genetic screening may be considered in this specific ethnic group. Similarly, such genetic screening may be considered in any ethnic group with a high <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> of known pathogenic variants.</div></li></ul><p><b>Family planning &#x02013; <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hi.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for a pregnancy at increased risk for the diffuse form of FHI-K<sub>ATP</sub> (involvement of beta cells throughout the pancreas) or for a pregnancy at increased risk of inheriting pathogenic variants causative of other types of diffuse FHI are possible. Parents who elect to continue a pregnancy in which the fetus has been determined to be affected have the advantage of initiating treatment immediately following birth, thus preventing early, severe hypoglycemia.</p><p>In families of individuals with focal FHI (pancreatic adenomatous hyperplasia that involves a limited region of the pancreas), <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> is not informative: while the paternal <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can be identified in the DNA of an at-risk fetus; no testing can identify which fetuses will also have a somatic event leading to loss of the maternal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</p></div></div><div id="hi.Resources"><h2 id="_hi_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Congenital Hyperinsulinism International (CHI)</b></div><div><b>Phone:</b> 973-544-8372</div><div><b>Email:</b> jraskin@congenitalhi.org</div><div><a href="http://congenitalhi.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.congenitalhi.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/congenital-hyperinsulinism" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Congenital hyperinsulinism</a></div></li></ul></div><div id="hi.References"><h2 id="_hi_References_">References</h2><div id="hi.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hi.REF.aguilarbryan.1999.101">Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. <span><span class="ref-journal">Endocr Rev. </span>1999;<span class="ref-vol">20</span>:101–35.</span> [<a href="/pubmed/10204114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10204114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.bahibuisson.2008.945">Bahi-Buisson N, Roze E, Dionisi C, Escande F, Valayannopoulos V, Feillet F, Heinrichs C, Chadefaux-Vekemans B, Dan B, de Lonlay P. Neurological aspects of hyperinsulinism-hyperammonaemia syndrome. <span><span class="ref-journal">Dev Med Child Neurol. </span>2008;<span class="ref-vol">50</span>:945–9.</span> [<a href="/pubmed/19046187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19046187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.beltrand.2012.198">Beltrand J, Caquard M, Arnoux JB, Laborde K, Velho G, Verkarre V, Rahier J, Brunelle F, Nihoul-F&#x000e9;k&#x000e9;t&#x000e9; C, Saudubray JM, Robert JJ, de Lonlay P. Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. <span><span class="ref-journal">Diabetes Care. </span>2012;<span class="ref-vol">35</span>:198–203.</span> [<a href="/pmc/articles/PMC3263917/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3263917</span></a>] [<a href="/pubmed/22190679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22190679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.ben_abdelaziz.2016.16">Ben Abdelaziz R, Ben Chehida A, Azzouz H, Boudabbous H, Lascols O, Ben Turkia H, Tebib N. A novel homozygous missense mutation in the insulin receptor gene results in an atypical presentation of Rabson-Mendenhall syndrome. <span><span class="ref-journal">Eur J Med Genet. </span>2016;<span class="ref-vol">59</span>:16–9.</span> [<a href="/pubmed/26691667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26691667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.burns.2008.65">Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. <span><span class="ref-journal">Pediatrics. </span>2008;<span class="ref-vol">122</span>:65–74.</span> [<a href="/pubmed/18595988" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18595988</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.cabezas.2017.2529">Cabezas OR, Flanagan SE, Stanescu H, Garc&#x000ed;a-Mart&#x000ed;nez E, Caswell R, Lango-Allen H, Ant&#x000f3;n-Gamero M, Argente J, Bussell AM, Brandli A, Cheshire C, Crowne E, Dumitriu S, Drynda R, Hamilton-Shield JP, Hayes W, Hofherr A, Iancu D, Issler N, Jefferies C, Jones P, Johnson M, Kesselheim A, Klootwijk E, Koettgen M, Lewis W, Martos JM, Mozere M, Norman J, Patel V, Parrish A, P&#x000e9;rez-Cerd&#x000e1; C, Pozo J, Rahman SA, Sebire N, Tekman M, Turnpenny PD, Hoff WV, Viering DHHM, Weedon MN, Wilson P, Guay-Woodford L, Kleta R, Hussain K, Ellard S, Bockenhauer D. Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promoter mutation in phosphomannomutase 2. <span><span class="ref-journal">J Am Soc Nephrol. </span>2017;<span class="ref-vol">28</span>:2529–39.</span> [<a href="/pmc/articles/PMC5533241/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5533241</span></a>] [<a href="/pubmed/28373276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28373276</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.christesen.2002.1240">Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, Brusgaard K, Massa O, Magnuson MA, Shiota C, Matschinsky FM, Barbetti F. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. <span><span class="ref-journal">Diabetes. </span>2002;<span class="ref-vol">51</span>:1240–6.</span> [<a href="/pubmed/11916951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11916951</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.clayton.2001.457">Clayton PT, Eaton S, Aynsley-Green A, Edginton M, Hussain K, Krywawych S, Datta V, Malingre HE, Berger R, van den Berg IE. Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. <span><span class="ref-journal">J Clin Invest. </span>2001;<span class="ref-vol">108</span>:457–65.</span> [<a href="/pmc/articles/PMC209352/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC209352</span></a>] [<a href="/pubmed/11489939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11489939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.cuestamu_oz.2004.2164">Cuesta-Mu&#x000f1;oz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, N&#x000e4;nt&#x000f6;-Salonen K, Rahier J, L&#x000f3;pez-Enriquez S, Garc&#x000ed;a-Gimeno MA, Sanz P, Soriguer FC, Laakso M. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. <span><span class="ref-journal">Diabetes. </span>2004;<span class="ref-vol">53</span>:2164–8.</span> [<a href="/pubmed/15277402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15277402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.di_candia.2009.1019">Di Candia S, Gessi A, Pepe G, Sogno Valin P, Mangano E, Chiumello G, Gianolli L, Proverbio MC, Mora S. Identification of a diffuse form of hyperinsulinemic hypoglycemia by 18-fluoro-L-3,4 dihydroxyphenylalanine positron emission tomography/CT in a patient carrying a novel mutation of the HADH gene. <span><span class="ref-journal">Eur J Endocrinol. </span>2009;<span class="ref-vol">160</span>:1019–23.</span> [<a href="/pubmed/19318379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19318379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.flanagan.2010.987">Flanagan SE, Kapoor RR, Mali G, Cody D, Murphy N, Schwahn B, Siahanidou T, Banerjee I, Akcay T, Rubio-Cabezas O, Shield JP, Hussain K, Ellard S. Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. <span><span class="ref-journal">Eur J Endocrinol. </span>2010;<span class="ref-vol">162</span>:987–92.</span> [<a href="/pmc/articles/PMC2857991/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2857991</span></a>] [<a href="/pubmed/20164212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20164212</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.flanagan.2011.e498">Flanagan SE, Patch AM, Locke JM, Akcay T, Simsek E, Alaei M, Yekta Z, Desai M, Kapoor RR, Hussain K, Ellard S. Genome-wide homozygosity analysis reveals HADH mutations as a common cause of diazoxide-responsive hyperinsulinemic-hypoglycemia in consanguineous pedigrees. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011;<span class="ref-vol">96</span>:E498–502.</span> [<a href="/pmc/articles/PMC3100671/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3100671</span></a>] [<a href="/pubmed/21252247" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21252247</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.flanagan.2017.320">Flanagan SE, Vairo F, Johnson MB, Caswell R, Laver TW, Lango Allen H, Hussain K, Ellard S. A. CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia. <span><span class="ref-journal">Pediatr Diabetes. </span>2017;<span class="ref-vol">18</span>:320–3.</span> [<a href="/pmc/articles/PMC5434855/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5434855</span></a>] [<a href="/pubmed/28318089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28318089</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.ferrara.2017.942">Ferrara CT, Boodhansingh KE, Paradies E, Fiermonte G, Steinkrauss LJ, Topor LS, Quintos JB, Ganguly A, De Leon DD, Palmieri F, Stanley CA. Novel hypoglycemia phenotype in congenital hyperinsulinism due to dominant mutations of uncoupling protein 2. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2017;<span class="ref-vol">102</span>:942–9.</span> [<a href="/pmc/articles/PMC5460685/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5460685</span></a>] [<a href="/pubmed/27967291" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27967291</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.fournet.2003.30">Fournet JC, Junien C. The genetics of neonatal hyperinsulinism. <span><span class="ref-journal">Horm Res. </span>2003;<span class="ref-vol">59</span> Suppl 1:30–4.</span> [<a href="/pubmed/12566718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12566718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.glaser.2011.891">Glaser B, Blech I, Krakinovsky Y, Ekstein J, Gillis D, Mazor-Aronovitch K, Landau H, Abeliovich D. ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia. <span><span class="ref-journal">Genet Med. </span>2011;<span class="ref-vol">13</span>:891–4.</span> [<a href="/pubmed/21716120" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21716120</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.glaser.1998.226">Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM, Herold KC. Familial hyperinsulinism caused by an activating glucokinase mutation. <span><span class="ref-journal">N Engl J Med. </span>1998;<span class="ref-vol">338</span>:226–30.</span> [<a href="/pubmed/9435328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9435328</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.glaser.1999.55">Glaser B, Landau H, Permutt MA. Neonatal hyperinsulinism. <span><span class="ref-journal">Trends Endocrinol Metab. </span>1999;<span class="ref-vol">10</span>:55–61.</span> [<a href="/pubmed/10322395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10322395</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.huopio.2000.897">Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko HL, Rahier J, Vauhkonen I, Kere J, Laakso M, Ashcroft F, Otonkoski T. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. <span><span class="ref-journal">J Clin Invest. </span>2000;<span class="ref-vol">106</span>:897–906.</span> [<a href="/pmc/articles/PMC381424/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC381424</span></a>] [<a href="/pubmed/11018078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11018078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.hussain.2004.163">Hussain K, Aynsley-Green A, Stanley CA. Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy (HI). <span><span class="ref-journal">Pediatr Endocrinol Rev. </span>2004;<span class="ref-vol">2</span> Suppl 1:163–7.</span> [<a href="/pubmed/16456495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16456495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.hussain.2003">Hussain K, Hindmarsh P, Aynsley-Green A. Neonates with symptomatic hyperinsulinemic hypoglycemia generate inappropriately low serum cortisol counterregulatory hormonal responses. J Clin Endocrinol Metab 2003;88: 4342e7. [<a href="/pubmed/12970308" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12970308</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.inder.2008.440">Inder T. How low can I go? The impact of hypoglycemia on the immature brain. <span><span class="ref-journal">Pediatrics. </span>2008;<span class="ref-vol">122</span>:440–1.</span> [<a href="/pubmed/18676561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18676561</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.katz.1999.3117">Katz LE, Ferry RJ Jr, Stanley CA, Collett-Solberg PF, Baker L, Cohen P. Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1999;<span class="ref-vol">84</span>:3117–24.</span> [<a href="/pubmed/10487673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10487673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.laver.2017.1442">Laver TW, Weedon MN, Caswell R, Hussain K, Ellard S, Flanagan SE. Analysis of large-scale sequencing cohorts does not support the role of variants in UCP2 as a cause of hyperinsulinaemic hypoglycaemia. <span><span class="ref-journal">Hum Mutat. </span>2017;<span class="ref-vol">38</span>:1442–4.</span> [<a href="/pmc/articles/PMC6815675/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6815675</span></a>] [<a href="/pubmed/28681398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28681398</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.le_quan_sang.2012.333">Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellann&#x000e9;-Chantelot C, Valayannopoulos V, Brassier A, Kayirangwa H, Barbier V, Broissand C, Fabreguettes JR, Charron B, Thalabard JC, de Lonlay P. Successful treatment of congenital hyperinsulinism with long-acting release octreotide. <span><span class="ref-journal">Eur J Endocrinol. </span>2012;<span class="ref-vol">166</span>:333–9.</span> [<a href="/pubmed/22048969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22048969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.mazoraronovitch.2009.424">Mazor-Aronovitch K, Landau H, Gillis D. Surgical versus non-surgical treatment of congenital hyperinsulinism. <span><span class="ref-journal">Pediatr Endocrinol Rev. </span>2009;<span class="ref-vol">6</span>:424–30.</span> [<a href="/pubmed/19396028" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19396028</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.meissner.1999.351">Meissner T, Beinbrech B, Mayatepek E. Congenital hyperinsulinism: molecular basis of a heterogeneous disease. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">13</span>:351–61.</span> [<a href="/pubmed/10338089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10338089</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.modanmoses.2011.2312">Modan-Moses D, Koren I, Mazor-Aronovitch K, Pinhas-Hamiel O, Landau H. Treatment of congenital hyperinsulinism with lanreotide acetate (SomatulineAutogel). <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011;<span class="ref-vol">96</span>:2312–7.</span> [<a href="/pubmed/21697252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21697252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.mohnike.2008a.65">Mohnike K, Blankenstein O, Minn H, Mohnike W, Fuchtner F, Otonkoski T. [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism. <span><span class="ref-journal">Horm Res. </span>2008a;<span class="ref-vol">70</span>:65–72.</span> [<a href="/pubmed/18547951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18547951</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.mohnike.2008b.59">Mohnike K, Blankenstein O, Pfuetzner A, P&#x000f6;tzsch S, Schober E, Steiner S, Hardy OT, Grimberg A, van Waarde WM. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. <span><span class="ref-journal">Horm Res. </span>2008b;<span class="ref-vol">70</span>:59–64.</span> [<a href="/pubmed/18493152" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18493152</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.molven.2004.221">Molven A, Matre GE, Duran M, Wanders RJ, Rishaug U, Nj&#x000f8;lstad PR, Jellum E, S&#x000f8;vik O. Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. <span><span class="ref-journal">Diabetes. </span>2004;<span class="ref-vol">53</span>:221–7.</span> [<a href="/pubmed/14693719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14693719</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.nestorowicz.1998.1119">Nestorowicz A, Glaser B, Wilson BA, Shyng SL, Nichols CG, Stanley CA, Thornton PS, Permutt MA. Genetic heterogeneity in familial hyperinsulinism. <span><span class="ref-journal">Hum Mol Genet. </span>1998;<span class="ref-vol">7</span>:1119–28.</span> [<a href="/pubmed/9618169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9618169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.nestorowicz.1997.1743">Nestorowicz A, Inagaki N, Gonoi T, Schoor KP, Wilson BA, Glaser B, Landau H, Stanley CA, Thornton PS, Seino S, Permutt MA. A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. <span><span class="ref-journal">Diabetes. </span>1997;<span class="ref-vol">46</span>:1743–8.</span> [<a href="/pubmed/9356020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9356020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.otonkoski.1999.408">Otonkoski T, Amm&#x000e4;l&#x000e4; C, Huopio H, Cote GJ, Chapman J, Cosgrove K, Ashfield R, Huang E, Komulainen J, Ashcroft FM, Dunne MJ, Kere J, Thomas PM. A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. <span><span class="ref-journal">Diabetes. </span>1999;<span class="ref-vol">48</span>:408–15.</span> [<a href="/pubmed/10334322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10334322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.otonkoski.2006.13">Otonkoski T, N&#x000e4;nt&#x000f6;-Salonen K, Sepp&#x000e4;nen M, Veijola R, Huopio H, Hussain K, Tapanainen P, Eskola O, Parkkola R, Ekstr&#x000f6;m K, Guiot Y, Rahier J, Laakso M, Rintala R, Nuutila P, Minn H. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. <span><span class="ref-journal">Diabetes. </span>2006;<span class="ref-vol">55</span>:13–8.</span> [<a href="/pubmed/16380471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16380471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.pinney.2013.18">Pinney SE, Ganapathy K, Bradfield J, Stokes D, Sasson A, Mackiewicz K, Boodhansingh K, Hughes N, Becker S, Givler S, Macmullen C, Monos D, Ganguly A, Hakonarson H, Stanley CA. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. <span><span class="ref-journal">Horm Res Paediatr. </span>2013;<span class="ref-vol">80</span>:18–27.</span> [<a href="/pmc/articles/PMC3876732/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3876732</span></a>] [<a href="/pubmed/23859901" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23859901</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.rahbari.2016.126">Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Turki SA, Dominiczak A, Morris A, Porteous D, Smith B, Stratton MR, Hurles ME, et al.  Timing, rates and spectra of human germline mutation. <span><span class="ref-journal">Nat Genet. </span>2016;<span class="ref-vol">48</span>:126–33.</span> [<a href="/pmc/articles/PMC4731925/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4731925</span></a>] [<a href="/pubmed/26656846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26656846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.sayed.2009.1419">Sayed S, Langdon DR, Odili S, Chen P, Buettger C, Schiffman AB, Suchi M, Taub R, Grimsby J, Matschinsky FM, Stanley CA. Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. <span><span class="ref-journal">Diabetes. </span>2009;<span class="ref-vol">58</span>:1419–27.</span> [<a href="/pmc/articles/PMC2682682/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2682682</span></a>] [<a href="/pubmed/19336674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19336674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.sempoux.2011.3785">Sempoux C, Capito C, Bellann&#x000e9;-Chantelot C, Verkarre V, de Lonlay P, Aigrain Y, Fekete C, Guiot Y, Rahier J. Morphological mosaicism of the pancreatic islets: a novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011;<span class="ref-vol">96</span>:3785–93.</span> [<a href="/pubmed/21956412" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21956412</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.stanley.2000.667">Stanley CA, Fang J, Kutyna K, Hsu BY, Ming JE, Glaser B, Poncz M. Molecular basis and characterization of the hyperinsulinism/hyperammonemia syndrome: predominance of mutations in exons 11 and 12 of the glutamate dehydrogenase gene. HI/HA Contributing Investigators. <span><span class="ref-journal">Diabetes. </span>2000;<span class="ref-vol">49</span>:667–73.</span> [<a href="/pubmed/10871207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10871207</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.thomas.1996.1809">Thomas P, Ye Y, Lightner E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. <span><span class="ref-journal">Hum Mol Genet. </span>1996;<span class="ref-vol">5</span>:1809–12.</span> [<a href="/pubmed/8923010" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8923010</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hi.REF.tornovsky.2004.6224">Tornovsky S, Crane A, Cosgrove KE, Hussain K, Lavie J, Heyman M, Nesher Y, Kuchinski N, Ben-Shushan E, Shatz O, Nahari E, Potikha T, Zangen D, Tenenbaum-Rakover Y, de Vries L, Argente J, Gracia R, Landau H, Eliakim A, Lindley K, Dunne MJ, Aguilar-Bryan L, Glaser B. Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and evidence for additional locus heterogeneity. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004;<span class="ref-vol">89</span>:6224–34.</span> [<a href="/pubmed/15579781" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15579781</span></a>]</div></li></ul></div></div><div id="hi.Chapter_Notes"><h2 id="_hi_Chapter_Notes_">Chapter Notes</h2><div id="hi.Author_History"><h3>Author History</h3><p>David Gillis, MD (2019-present)<br />Benjamin Glaser, MD; Hadassah-Hebrew University Medical Center (2003-2019)</p></div><div id="hi.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>21 March 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 January 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 June 2010 (cd) Revision: prenatal testing for <i>HADH</i> mutations available on a clinical basis</div></li><li class="half_rhythm"><div>23 February 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 August 2003 (me) Review posted live</div></li><li class="half_rhythm"><div>12 May 2003 (bg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1375</span><span class="label">PMID: <a href="/pubmed/20301549" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301549</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hyperchol/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/lpl/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1375&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1375/?report=reader">PubReader</a></li><li><a href="/books/NBK1375/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1375" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1375" style="display:none" title="Cite this Page"><div class="bk_tt">Gillis D. Familial Hyperinsulinism. 2003 Aug 19 [Updated 2019 Mar 21]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1375/pdf/Bookshelf_NBK1375.pdf">PDF version of this page</a> (476K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hi.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hi._escape__1_Clinical_Characteristics_o" ref="log$=inpage&amp;link_id=inpage">1. Clinical Characteristics of Familial Hyperinsulinism</a></li><li><a href="#hi._escape__2_Genetic_Causes_of_Familial" ref="log$=inpage&amp;link_id=inpage">2. Genetic Causes of Familial Hyperinsulinism</a></li><li><a href="#hi._escape__3_Evaluation_Strategies_to_I" ref="log$=inpage&amp;link_id=inpage">3. Evaluation Strategies to Identify the Genetic Cause of Familial Hyperinsulinism in a Proband</a></li><li><a href="#hi._escape__4_Medical_Management_of_FHI" ref="log$=inpage&amp;link_id=inpage">4. Medical Management of FHI Based on Genetic Cause</a></li><li><a href="#hi._escape__5_Risk_Assessment_and_Survei" ref="log$=inpage&amp;link_id=inpage">5. Risk Assessment and Surveillance of At-Risk Relatives for Early Detection and Treatment of FHI</a></li><li><a href="#hi.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hi.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hi.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6833[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ABCC8</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3643[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">INSR</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3033[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HADH</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2645[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GCK</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6566[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SLC16A1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2746[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">GLUD1</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3767[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">KCNJ11</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3172[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HNF4A</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1470108" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1470108" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29792621" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Maturity-Onset Diabetes of the Young Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Maturity-Onset Diabetes of the Young Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Naylor R, Knight Johnson A, del Gaudio D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31119523" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Congenital Hyperinsulinemic Hypoglycemia and Hyperammonemia due to Pathogenic Variants in GLUD1.</a><span class="source">[Indian J Pediatr. 2019]</span><div class="brieflinkpop offscreen_noflow">Congenital Hyperinsulinemic Hypoglycemia and Hyperammonemia due to Pathogenic Variants in GLUD1.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Roy K, Satapathy AK, Houhton JAL, Flanagan SE, Radha V, Mohan V, Sharma R, Jain V. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Indian J Pediatr. 2019 Nov; 86(11):1051-1053. Epub 2019 May 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19254908" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The genetic basis of congenital hyperinsulinism.</a><span class="source">[J Med Genet. 2009]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The genetic basis of congenital hyperinsulinism.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">James C, Kapoor RR, Ismail D, Hussain K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Med Genet. 2009 May; 46(5):289-99. Epub 2009 Mar 1.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23345197" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism.</a><span class="source">[Eur J Endocrinol. 2013]</span><div class="brieflinkpop offscreen_noflow">Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kapoor RR, Flanagan SE, Arya VB, Shield JP, Ellard S, Hussain K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Endocrinol. 2013 Apr; 168(4):557-64. Epub 2013 Mar 15.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23275527" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Genotype and phenotype correlations in 417 children with congenital hyperinsulinism.</a><span class="source">[J Clin Endocrinol Metab. 2013]</span><div class="brieflinkpop offscreen_noflow">Genotype and phenotype correlations in 417 children with congenital hyperinsulinism.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Snider KE, Becker S, Boyajian L, Shyng SL, MacMullen C, Hughes N, Ganapathy K, Bhatti T, Stanley CA, Ganguly A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Endocrinol Metab. 2013 Feb; 98(2):E355-63. Epub 2012 Dec 28.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301549" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301549" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040d3c39a66ee2ba5762db">Familial Hyperinsulinism - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Familial Hyperinsulinism - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:30:36-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D25FCE03FD8F10000000005FC0221&amp;ncbi_session=CE8D25FCE040D3B1_1532SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1375%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1375&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1375/&amp;ncbi_pagename=Familial Hyperinsulinism - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D25FCE040D3B1_1532SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>